The U.K. Medicines and Healthcare products Regulatory Agency, the country’s equivalent of the FDA, approved AstraZeneca’s vaccine for use in those 18 years or older, recommending the two doses be administered within an interval of four to 12 weeks.
The drugmaker said it is working with the U.K. government to distribute doses as quickly as possible, potentially allowing for shots to be administered in early January.
The vaccine, which uses a chimpanzee viral vector based on a weakened version of an adenovirus, costs $3 to $4 a dose and can be stored in normal refrigerated conditions. It is cheaper and easier to store than the mRNA vaccines developed by Pfizer and Moderna, which received FDA emergency use approval Dec. 11 and Dec. 18, respectively.
More articles on pharmacy:
7 recent drug, device approvals
Judge blocks Trump’s ‘most favored nation’ drug pricing rule
Moderna vaccine linked to allergic reaction
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.